Bristol Myers Squibb's CAR T cell therapy Breyanzi receives US FDA approval for relapsed or refractory follicular ...
Bristol Myers Squibb announced the US FDA has granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory …